Submerge in the Oligonucleotide Emerge: Best Practices for Developing These Complex Biologics

In the last few years, the pharmaceutical industry has invested in developing Complex Biologics including proteins, oligonucleotides, viral vectors, and engineered cells. One area within Complex Biologics experiencing tremendous growth is oligonucleotide therapies— nucleic acid polymers with the potential to treat or manage a wide range of diseases.

Certara supported the first FDA approval of an oligonucleotide therapy as well as 23 subsequent programs. Watch this free webinar to learn how we can help you accelerate your drug development program. Our experts explained how clinical pharmacology, pharmacometrics, and regulatory science solutions can help oligonucleotide drug developers overcome key challenges.

---- Time Stamps ----
0:00​ Intro to oligonucleotides
10:35 Oligonucleotides: Transitioning from animals to humans
35:34 Clinical pharmacology considerations